GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » Days Sales Outstanding

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Days Sales Outstanding : 108.09 (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries Days Sales Outstanding?

Taro Pharmaceutical Industries's average Accounts Receivable for the three months ended in Dec. 2023 was $186.1 Mil. Taro Pharmaceutical Industries's Revenue for the three months ended in Dec. 2023 was $157.1 Mil. Hence, Taro Pharmaceutical Industries's Days Sales Outstanding for the three months ended in Dec. 2023 was 108.09.

The historical rank and industry rank for Taro Pharmaceutical Industries's Days Sales Outstanding or its related term are showing as below:

TARO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.15   Med: 117.11   Max: 149.72
Current: 119.72

During the past 13 years, Taro Pharmaceutical Industries's highest Days Sales Outstanding was 149.72. The lowest was 62.15. And the median was 117.11.

TARO's Days Sales Outstanding is ranked worse than
82.6% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 71.68 vs TARO: 119.72

Taro Pharmaceutical Industries's Days Sales Outstanding declined from Dec. 2022 (162.89) to Dec. 2023 (108.09).


Taro Pharmaceutical Industries Days Sales Outstanding Historical Data

The historical data trend for Taro Pharmaceutical Industries's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries Days Sales Outstanding Chart

Taro Pharmaceutical Industries Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 121.07 133.93 149.19 149.72 143.09

Taro Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 162.89 125.91 123.22 125.59 108.09

Competitive Comparison of Taro Pharmaceutical Industries's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taro Pharmaceutical Industries's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's Days Sales Outstanding falls into.



Taro Pharmaceutical Industries Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Taro Pharmaceutical Industries's Days Sales Outstanding for the fiscal year that ended in Mar. 2023 is calculated as

Days Sales Outstanding (A: Mar. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2022 ) + Accounts Receivable (A: Mar. 2023 )) / count ) / Revenue (A: Mar. 2023 )*Days in Period
=( (246.972 + 202.26) / 2 ) / 572.952*365
=224.616 / 572.952*365
=143.09

Taro Pharmaceutical Industries's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (181.064 + 191.232) / 2 ) / 157.145*365 / 4
=186.148 / 157.145*365 / 4
=108.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taro Pharmaceutical Industries  (NYSE:TARO) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Taro Pharmaceutical Industries Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Executives
Sun Pharma Global Inc 10 percent owner
Sun Pharmaceutical Industries Ltd 10 percent owner, other: Affiliated Party 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd. 10 percent owner KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc 10 percent owner FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Headlines

From GuruFocus

Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.

By Business Wire Business Wire 09-28-2020

Taro to Release Full Year Results on May 23, 2023

By Business Wire Business Wire 05-18-2023

Taro to Announce Second Quarter Results on October 28, 2021

By Business Wire Business Wire 10-21-2021

Taro to Announce Second Quarter Results on October 28, 2020

By Business Wire Business Wire 10-22-2020

Taro Achieves Global Resolution of DOJ Antitrust Investigations

By Business Wire Business Wire 07-24-2020

Taro to Release First Quarter Results on July 27, 2022

By Business Wire Business Wire 07-26-2022

Taro to Announce First Quarter Results on July 27, 2021

By Business Wire Business Wire 07-21-2021